Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
PolyPid Ltd
PYPD | US
4.87
USD-0.20
-3.94%
PYPD | US
About PolyPid Ltd
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
02/06/2026
Close
4.87
Open
5.13
High
5.21
Low
4.80
PolyPid Ltd. a clinical-stage pharmaceutical company develops manufactures and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100 which helps in the prevention of sternal (bone) surgical site infections (SSIs) as well as for the prevention of abdominal (soft tissue) SSIs. It is also developing OncoPLEX for the treatment of intra-tumoral cancer. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva Israel.
View LessPYPD | US
Risk
55.1
Sharpe
1.52
Luna's Score
45/100
Recommendation
Sell
Luna says (PYPD | US)
What's Working
Positive Momentum
Strong Sharpe Ratio (> 1.2)
What's not Working
Weakness based on declining price with high volume
High Short-term Volatility
Microcap (<300M USD)
High Market Beta (> 0.8)
High Debt to Equity (> 0.75)
High Debt to Asset (> 0.45)
Rich in Valuation (Price to Book > 8)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
10 days
54.1%1 month
55.1%3 months
46.8%6 months
44.9%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
14.58
Debt to equity
6.89
Debt to assets
0.56
Ent. to EBITDA
-0.36
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-21.95M
MarketCap
33.13M
MarketCap(USD)
33.13M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-496.62
Short ratio
1.89
Short perc.
0.13
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
0.61
Range1M
1.03
Range3M
1.18
Volumes: Market Activity
Rel. volume
1.42
Price X volume
935.69K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -0.36 | - | Cheaper |
| Ent. to Revenue | - | - | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 14.58 | 15.55 | Par |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 46.76 | - | Lower Risk |
| Debt to Equity | 6.89 | -1.23 | Expensive |
| Debt to Assets | 0.56 | 0.25 | Expensive |
| Market Cap | 33.13M | - | Emerging |
